argenx SE American Depositary Shares (ARGX) Price and Market Data

argenx SE is a Dutch biopharmaceutical company dedicated to developing antibody-based therapies for rare autoimmune diseases. Its lead product, Vyvgart (efgartigimod), received FDA approval in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, the company also secured FDA approval for Vyvgart Hytrulo, a subcutaneous version of Vyvgart that provides a more convenient alternative to intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder affecting the peripheral nervous system. argenx SE continues to emphasize innovation while advancing a pipeline that includes potential treatments for primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.